XML 27 R20.htm IDEA: XBRL DOCUMENT
v3.25.3

Revenue and Segment Information | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Revenue and Segment Information | 11. Revenue and Segment Information Disaggregated Revenue The Company disaggregates revenue from contracts with customers related to OCS transplant by organ type and geographical area as it believes this presentation best depicts how the nature, amount, timing and uncertainty of the Company’s revenue and cash flows are affected by economic factors, as shown below (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
OCS transplant revenue by country by organ(1)(2): |  |  |  |  |  |  |  |  |  |  |  |
United States |  |  |  |  |  |  |  |  |  |  |  |
Lung total revenue |  | $ | 3,725 |  |  | $ | 3,726 |  |  | $ | 11,515 |  |  | $ | 12,675 |
Heart total revenue |  |  | 27,401 |  |  |  | 24,525 |  |  |  | 85,838 |  |  |  | 71,922 |
Liver total revenue |  |  | 107,883 |  |  |  | 76,671 |  |  |  | 332,460 |  |  |  | 220,636 |
Total United States OCS transplant revenue |  |  | 139,009 |  |  |  | 104,922 |  |  |  | 429,813 |  |  |  | 305,233 |
All other countries |  |  |  |  |  |  |  |  |  |  |  |
Lung revenue |  |  | 385 |  |  |  | 182 |  |  |  | 1,181 |  |  |  | 1,590 |
Heart revenue |  |  | 3,187 |  |  |  | 2,401 |  |  |  | 10,232 |  |  |  | 9,800 |
Liver revenue |  |  | 58 |  |  |  | — |  |  |  | 442 |  |  |  | — |
Total all other countries OCS transplant revenue |  |  | 3,630 |  |  |  | 2,583 |  |  |  | 11,855 |  |  |  | 11,390 |
Total OCS transplant revenue |  | $ | 142,639 |  |  | $ | 107,505 |  |  | $ | 441,668 |  |  | $ | 316,623 |
(1) Revenue by country is categorized based on the location of the end customer. Total OCS transplant revenue includes product and service revenue. (2) Service revenue unrelated to OCS transplant, which was $1.2 million and $3.1 million for the three and nine months ended September 30, 2025, respectively, and $1.3 million and $3.3 million for the three and nine months ended September 30, 2024, respectively, is not included in this table. Payments to Customers In connection with its clinical trials, the Company makes payments to customers for reimbursement of clinical trial materials and customer’s costs incurred to execute specific clinical trial protocols related to the Company’s OCS products, which are recorded as a reduction of revenue. The Company records the reduction of revenue and a corresponding accrual for its estimate of the payments in the same period as the revenue is recognized. The Company updates its accrual estimates as information related to these payments is received with a corresponding adjustment to revenue. For each of the three and nine months ended September 30, 2025 and 2024, the net impact of adjustments to revenue for such payments was insignificant. The Company also makes payments to customers to obtain information related to post-approval studies or existing standard-of-care protocols unrelated to the Company's OCS products and records such payments as operating expenses. For the three and nine months ended September 30, 2025, the Company recorded $1.3 million and $4.3 million, respectively, of operating expense related to these costs. For the three and nine months ended September 30, 2024, the Company recorded $1.8 million and $4.5 million, respectively, of operating expense related to these costs. Segment Information The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the Company’s chief operating decision maker, or decision-making group (the “CODM”), in deciding how to allocate resources and assess performance. The CODM of the Company is the Chief Executive Officer. The CODM assesses performance and allocates resources based on the Company’s consolidated statements of operations and the Company’s operations are managed on a consolidated basis to decide where to allocate and invest additional resources within the business to continue growth. The CODM also utilizes the consolidated balance sheet for resource allocation and segment asset information is not provided to the CODM to allocate resources. As a single reportable segment entity, the Company’s segment performance measure is net income (loss). Significant segment expenses, as provided to the CODM, are presented below (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Total revenue |  | $ | 143,823 |  |  | $ | 108,761 |  |  | $ | 444,730 |  |  | $ | 319,916 |
Less: |  |  |  |  |  |  |  |  |  |  |  |
Cost of net product revenue |  |  | 18,687 |  |  |  | 13,246 |  |  |  | 54,420 |  |  |  | 41,800 |
Cost of service revenue |  |  | 40,561 |  |  |  | 34,670 |  |  |  | 120,918 |  |  |  | 88,048 |
Research, development and clinical trials: |  |  |  |  |  |  |  |  |  |  |  |
Personnel related (including stock-based compensation expense) |  |  | 6,444 |  |  |  | 5,462 |  |  |  | 18,660 |  |  |  | 16,204 |
Laboratory supplies and research materials |  |  | 2,992 |  |  |  | 3,085 |  |  |  | 13,154 |  |  |  | 9,332 |
Consulting and third-party services |  |  | 3,432 |  |  |  | 3,859 |  |  |  | 9,907 |  |  |  | 8,504 |
Clinical trials costs |  |  | 278 |  |  |  | 182 |  |  |  | 626 |  |  |  | 452 |
Facility related and other |  |  | 2,114 |  |  |  | 1,678 |  |  |  | 6,007 |  |  |  | 5,012 |
Selling, general and administrative: |  |  |  |  |  |  |  |  |  |  |  |
Personnel related (including stock-based compensation expense) |  |  | 29,234 |  |  |  | 28,188 |  |  |  | 84,212 |  |  |  | 79,567 |
Professional and consultant fees |  |  | 6,395 |  |  |  | 4,086 |  |  |  | 19,649 |  |  |  | 12,636 |
NOP support |  |  | 1,173 |  |  |  | 3,558 |  |  |  | 5,511 |  |  |  | 9,101 |
Tradeshows and conferences |  |  | 1,076 |  |  |  | 353 |  |  |  | 3,051 |  |  |  | 3,218 |
Facility related and other |  |  | 8,137 |  |  |  | 6,471 |  |  |  | 21,305 |  |  |  | 17,190 |
Other segment items(1) |  |  | (1,019 | ) |  |  | (293 | ) |  |  | 2,402 |  |  |  | 245 |
Net income |  | $ | 24,319 |  |  | $ | 4,216 |  |  | $ | 84,908 |  |  | $ | 28,607 |
(1) Other segment items include interest income, interest expense, foreign currency exchange gains and losses and income taxes. See the condensed consolidated financial statements for other financial information regarding the Company’s operating segment.

X
- Definition The entire disclosure of revenue from contracts with customers to transfer good or service and reporting segments including data and tables. + References No definition available. + Details
Name: | tmdx_RevenueAndSegmentInformationDisclosureTextBlock
Namespace Prefix: | tmdx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration